Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for PVP-I  COVID-19 treatment studies for Povidone-Iod..  C19 studies: Povidone-Iod..  Povidone-Iod..   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Fold change 33% Improvement Relative Risk c19early.org/p Seneviratne et al. Povidone-Iodine for COVID-19 RCT LATE Does late treatment with povidone-iodine reduce short-term viral load? RCT 6 patients in Singapore Improved viral load with povidone-iodine (p=0.01) Seneviratne et al., Infection, doi:10.1007/s15010-020-01563-9 Favors povidone-iodine Favors control
Efficacy of commercial mouth-rinses on SARS-CoV-2 viral load in saliva: randomized control trial in Singapore
Seneviratne et al., Infection, doi:10.1007/s15010-020-01563-9
Seneviratne et al., Efficacy of commercial mouth-rinses on SARS-CoV-2 viral load in saliva: randomized control trial in Singapore, Infection, doi:10.1007/s15010-020-01563-9
Dec 2020   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Small mouthwash RCT with 4 PVP-I patients and 2 water patients concluding that PVP-I may have a sustained effect on reducing the salivary SARS-CoV-2 level in COVID-19 patients. ISRCTN95933274.
relative fold change, 32.9% better, RR 0.67, p < 0.01, treatment 4, control 2, PVP-I vs. water, 6 hours.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Seneviratne et al., 14 Dec 2020, Randomized Controlled Trial, Singapore, peer-reviewed, 12 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperPovidone-Iod..All
Abstract: Infection (2021) 49:305–311 https://doi.org/10.1007/s15010-020-01563-9 ORIGINAL PAPER Efficacy of commercial mouth‑rinses on SARS‑CoV‑2 viral load in saliva: randomized control trial in Singapore Chaminda J. Seneviratne1,2 · Preethi Balan1,2 · Kwan Ki Karrie Ko3 · Nadeeka S. Udawatte1 · Deborah Lai3 · Dorothy Hui Lin Ng4 · Indumathi Venkatachalam4 · Kheng Sit Lim5 · Moi Lin Ling6 · Lynette Oon3 · Bee Tin Goh1,2 · Xiang Ying Jean Sim4 Received: 25 September 2020 / Accepted: 24 November 2020 / Published online: 14 December 2020 © Springer-Verlag GmbH Germany, part of Springer Nature 2020 Abstract Purpose One of the key approaches to minimize the risk of COVID-19 transmission would be to reduce the titres of SARSCoV-2 in the saliva of infected COVID-19 patients. This is particularly important in high-risk procedures like dental treatment. The present randomized control trial evaluated the efficacy of three commercial mouth-rinse viz. povidone–iodine (PI), chlorhexidine gluconate (CHX) and cetylpyridinium chloride (CPC), in reducing the salivary SARS-CoV-2 viral load in COVID-19 patients compared with water. Methods A total of 36 SARS-CoV-2-positive patients were recruited, of which 16 patients were randomly assigned to four groups—PI group (n = 4), CHX group (n = 6), CPC group (n = 4) and water as control group (n = 2). Saliva samples were collected from all patients at baseline and at 5 min, 3 h and 6 h post-application of mouth-rinses/water. The samples were subjected to SARS-CoV-2 RT-PCR analysis. Results Comparison of salivary Ct values of patients within each group of PI, CHX, CPC and water at 5 min, 3 h and 6 h time points did not show any significant differences. However, when the Ct value fold change of each of the mouth-rinse group patients were compared with the fold change of water group patients at the respective time points, a significant increase was observed in the CPC group patients at 5 min and 6 h and in the PI group patients at 6 h. Conclusion The effect of decreasing salivary load with CPC and PI mouth-rinsing was observed to be sustained at 6 h time point. Within the limitation of the current study, as number of the samples analyzed, the use of CPC and PI formulated that commercial mouth-rinses may be useful as a pre-procedural rinse to help reduce the transmission of COVID-19. ISRCTN (ISRCTN95933274), 09/09/20, retrospectively registered Keyword COVID-19 · SARS-CoV-2 · Mouth-rinses · Saliva · Clinical trial · Antiseptics
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit